Graft-versus-host Disease (GVHD)

Immunology·MeSH: Graft vs Host Disease

10 drugs in development·2 companies·3 clinical trials

Drug Pipeline by Phase

Phase 3(8)

Drug	Company
extracorporeal photopheresis	Incyte Corp. (INCY)
imatinib	Incyte Corp. (INCY)
infliximab	Incyte Corp. (INCY)
itacitinib	Incyte Corp. (INCY)
mechanistic target of rapamycin inhibitors	Incyte Corp. (INCY)
mycophenolate mofetil	Incyte Corp. (INCY)
pentostatin	Incyte Corp. (INCY)
tacrolimus	Incyte Corp. (INCY)

Phase 1(1)

Drug	Company
amt-126	Applied Molecular Transport Inc. (AMTI)

Phase 4(1)

Drug	Company
ibrutinib	Incyte Corp. (INCY)

BioSniper tracks 10 drugs in development for Graft-versus-host Disease (GVHD) across 2 companies.

There are 3 clinical trials targeting Graft-versus-host Disease (GVHD) tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.